Mark Munch Sells 2,000 Shares of Bruker (NASDAQ:BRKR) Stock

Key Points

• Mark Munch, Bruker VP, sold 2,000 shares on April 15 at an average price of $39.90 for $79,800, trimming his stake by 1.53% to 128,443 shares; he previously sold 2,000 shares on March 13 at $35.44.
• Bruker missed quarterly EPS estimates ($0.59 vs. $0.65) but beat revenue at $977.2M and set FY2026 guidance of 2.10–2.15 EPS; analysts have a consensus "Hold" rating with a $49.38 price target.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mark Munch also recently made the following trade(s):

• On Friday, March 13th, Mark Munch sold 2,000 shares of Bruker stock. The shares were sold at an average price of $35.44, for a total value of $70,880.00.

Bruker Price Performance

NASDAQ BRKR traded down $0.54 during trading hours on Thursday, reaching $38.94. 1,512,251 shares of the stock traded hands, compared to its average volume of 2,314,501. The company has a market cap of $5.93 billion, a price-to-earnings ratio of -259.60, a price-to-earnings-growth ratio of 2.39 and a beta of 1.20. The stock has a 50 day simple moving average of $37.51 and a two-hundred day simple moving average of $41.70. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to analysts' expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm's quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker's payout ratio is currently -133.33%.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently modified their holdings of the company. Orbis Allan Gray Ltd purchased a new stake in Bruker in the 2nd quarter worth $192,735,000. Price T Rowe Associates Inc. MD increased its stake in Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock worth $111,488,000 after buying an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC increased its stake in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after buying an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. increased its stake in Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock worth $108,796,000 after buying an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Bruker by 222.6% in the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company's stock worth $86,663,000 after buying an additional 1,269,316 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BRKR has been the topic of a number of research analyst reports. Guggenheim dropped their target price on Bruker from $58.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, March 30th. The Goldman Sachs Group dropped their target price on Bruker from $40.00 to $35.00 and set a "sell" rating on the stock in a report on Friday, February 13th. Weiss Ratings reissued a "sell (d+)" rating on shares of Bruker in a report on Friday, March 27th. Jefferies Financial Group set a $50.00 target price on Bruker in a report on Thursday, February 12th. Finally, UBS Group reissued a "neutral" rating and issued a $49.00 target price on shares of Bruker in a report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $49.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.